Fresenius Kabi Reports the US FDA's Acceptance of BLA for its MSB11455 (biosimilar- pegfilgrastim)
Shots:
- The BLA submission is based on analytical- PK/ PD- safety and immunogenicity data from two clinical studies that demonstrated equivalent PK/ PD profile to Neulasta- similar immunogenicity & comparable safety profile in healthy volunteers
- The BLA represents Fresenius Kabi’s first biosimilar candidate submitted to the FDA. Additionally- Fresenius Kabi also received EMA’s acceptance for review MAA of MSB11455 on May 22- 2020
- MSB11455 is a biosimilar referencing Amgen’s Neulasta- acts by stimulating the growth of WBCs. Neulasta is indicated to decrease the incidence of infection- as manifested by febrile neutropenia- in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with febrile neutropenia in the US
Click here to read full press release/ article | Ref: Fresenius Kabi | Image: Fresenius Kabi
Related News: Fresenius Kabi Reports EMA’s Acceptance of MAA for its MSB11455 (biosimilar- pegfilgrastim)
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
